About one in six adults of age 60 or older are affected by Mild Neurocognitive Disorder (Mild Cognitive Impairment MCI) or Mild Behavioral Impairment (MBI). Detection of these syndromes which is often missed by clinicians has become increasingly important as a consequence of new advances in clinical and biomarker research and the availability of new preventive and treatment interventions. Dementia once viewed as an entity unto itself is now understood to represent the final stage of disease processes which can be revealed during a clinically silent presymptomatic phase or during a mildly symptomatic cognitive or behavioral stage. Etiologic classification too has evolved to take into account the presence or absence of biomarkers such as beta amyloid phosphorylated tau protein or nonspecific neurodegenerative changes which help clinicians to match interventions to the patients most likely to benefit. Recent research into preventive interventions and the recent FDA approval of disease modifying treatments for MCI or early stage Alzheimer’s dementia have increased public interest in early detection and precision medicine approaches. Concurrently cognitive decline risk factors have been increasingly understood and this has engendered preventive non-pharmacologic programs such as Brain-WISE developed at Universitiy of Delaware. This symposium will provide Behavioral Health clinicians with an understanding of the evolving syndromal definitions preventive interventions biomarker-based detection and cutting edge treatments. A special aspect of this course will be discussion of how MBI can be recognized differentiated from primary psychiatric disorders and managed effectively.
Format
Recorded webinar, non-interactive, self-paced distance learning activity.
This presentation was recorded at the 2025 American Psychiatric Association Annual Meeting.
Learning Objectives
- The attendee will define Mild Cognitive Impairment and Mild Behavioral Impairment and list new criteria for diagnosis.
- The attendee will learn how to improve detection of MCI or MBI through questionnaires blood tests and imaging studies based on biomarker research findings.
- The attendee will be able to describe a population-based approach to preventing or delaying cognitive decline.
- The attendee will learn about the new disease-modifying medications for MCI-AD and Early Alzheimer’s Disease.
Target Audience
Medical Students, Residents/Fellows, Psychiatrists
Estimated Time to Complete
Estimated Duration: 1.5 hours
Begin Date: April 1, 2026
End Date: April 1, 2029
How to Earn Credit
Participants who wish to earn 1.5 AMA PRA Category 1 Credit ™ or a certificate of participation may do so by completing all sections of the course including the evaluation. After evaluating the program, course participants will be provided with an opportunity to claim hours of participation and print an official CME certificate (physicians) or certificate of participation (non-physicians) showing the event date and hours earned.
Continuing Education Credit
In support of improving patient care, the American Psychiatric Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
The APA designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Faculty and Planner Disclosures
The American Psychiatric Association adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Medical Education. Any individuals in a position to control the content of a CME activity — including faculty, planners, reviewers or others — are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Program Presenters
- James Ellison, M.D., M.P.H.
- Sehba Husain-Krautter, M.D., Ph.D.
- Matthew Cohen, Ph.D.
Program Planners
- Vishal Madaan, MD. Chief of Education and Deputy Medical Director, APA.
Accessibility for Participants with Disabilities
The American Psychiatric Association is committed to ensuring accessibility of its website to people with disabilities. If you have trouble accessing any of APA’s online resources, please contact us at 202-559-3900 for assistance.
Technical Requirements
This internet-based CME activity is best experienced using any of the following:
- The latest and 2nd latest public versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer 11+
This Web site requires that JavaScript and session cookies be enabled. Certain activities may require additional software to view multimedia, presentation, or printable versions of the content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Acrobat Reader, Microsoft PowerPoint, and Windows Media Player.
Optimal System Configuration:
- Browser: Google Chrome (latest and 2nd latest version), Safari (latest and 2nd latest version), Internet Explorer 11.0+, Firefox (latest and 2nd latest version), or Microsoft Edge (latest and 2nd latest version)
- Operating System: Windows versions 8.1+, Mac OS X 10.5 (Leopard) +, Android (latest and 2nd latest version), or iOS/iPad OS (latest and 2nd latest version)
- Internet Connection: 1 Mbps or higher
Minimum Requirements:
- Windows PC: Windows 8.1 or higher; 1 GB (for 32-bit)/2 GB (for 64-bit) or higher RAM; Microsoft DirectX 9 graphics device with WDDM driver; audio playback with speakers for programs with video content
- Macintosh: Mac OS X 10.5 or higher with latest updates installed; Intel, PowerPC G5, or PowerPC G4 (867MHz or faster) processor; 512 MB or higher RAM; audio playback with speakers for programs with video content
For assistance: Contact educme@psych.org for questions about this activity | Contact learningcenter@psych.org for technical assistance